Nolan Capital

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Rocky Mountain Recreation Company specializes in the management of recreational sites for federal, state, and local agencies. The company offers a comprehensive range of services, including the maintenance and management of campgrounds, marinas, and water recreation facilities. In addition to operational support, it provides amenities such as fast food services, fuel docks, boat rentals, and bait and tackle shops, along with the sale of various sundry items. By focusing on these services, Rocky Mountain Recreation Company aims to enhance the recreational potential of natural environments while ensuring their preservation and sustainability.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company specializes in developing treatments that target nonworking or missing genes by introducing healthy copies back into the body to restore function. This approach aims to address significant unmet needs in healthcare by expediting the development of gene therapies from research to clinical application as safely and quickly as possible.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. Utilizing its proprietary platform, the company identifies genomic sequences that regulate gene expression, facilitating advancements in viral gene therapy. Encoded Therapeutics has a diverse therapy pipeline targeting various genetic and acquired disorders across multiple disease pathways, including neurocircuitry, metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, the company is dedicated to improving patient outcomes through innovative gene therapy solutions.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.